Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement, impacting overall financial performance [1]. Financial Performance - Total revenue for the period was 13.273 billion RMB, representing a year-on-year decrease of 18.5% [1]. - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% compared to the previous year [1]. - Basic earnings per share were 22.29 cents [1]. Dividend Announcement - The company proposed an interim dividend of 0.14 HKD per share, down from 0.16 HKD in the same period last year [1]. Gross Margin Analysis - The gross margin for the period decreased by 6.0 percentage points to 65.6%, primarily due to a reduced revenue contribution from the prescription drug business [1].
石药集团午后一度跌超4% 上半年纯利同比减少15.64% 中期息14港仙